help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gozes, I.
Right arrow Articles by Fridkin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gozes, I.
Right arrow Articles by Fridkin, M.

Endocrinology, Vol 134, 2121-2125, Copyright © 1994 by Endocrine Society

ARTICLES

Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment

I Gozes, A Reshef, D Salah, S Rubinraut and M Fridkin
Department of Chemical Pathology, Sackler School of Medicine, Tel Aviv University, Israel.

The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. J. Harmar, W. J. Sheward, C. F. Morrison, B. Waser, M. Gugger, and J. C. Reubi
Distribution of the VPAC2 Receptor in Peripheral Tissues of the Mouse
Endocrinology, March 1, 2004; 145(3): 1203 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. G. Juarranz, J. Van Rampelbergh, P. Gourlet, P. De Neef, J. Cnudde, P. Robberecht, and M. Waelbroeck
Different Vasoactive Intestinal Polypeptide Receptor Domains Are Involved in the Selective Recognition of Two VPAC2-Selective Ligands
Mol. Pharmacol., December 1, 1999; 56(6): 1280 - 1287.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Gozes, O. Perl, E. Giladi, A. Davidson, O. Ashur-Fabian, S. Rubinraut, and M. Fridkin
Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design
PNAS, March 30, 1999; 96(7): 4143 - 4148.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Gressens, L. Besse, P. Robberecht, I. Gozes, M. Fridkin, and P. Evrard
Neuroprotection of the Developing Brain by Systemic Administration of Vasoactive Intestinal Peptide Derivatives
J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1207 - 1213.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
A. J. Harmar, A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al.
International Union of Pharmacology. XVIII. Nomenclature of Receptors for Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide
Pharmacol. Rev., June 1, 1998; 50(2): 265 - 270.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society